Stockreport

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotypeApproval based [Read more]